tradingkey.logo

Bone Biologics Corp

BBLG

4.769USD

-0.510-9.67%
Close 06/13, 16:00ETQuotes delayed by 15 min
15.60MMarket Cap
LossP/E TTM

Bone Biologics Corp

4.769

-0.510-9.67%
More Details of Bone Biologics Corp Company
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Company Info
Ticker SymbolBBLG
Company nameBone Biologics Corp
IPO dateNov 27, 2015
Founded at2007
CEOMr. Jeffrey Frelick
Number of employees2
Security typeOrdinary Share
Fiscal year-endNov 27
Address2 Burlington Woods Dr Ste 100
CityBURLINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01803-4551
Phone17815524452
Websitehttps://www.bonebiologics.com/
Ticker SymbolBBLG
IPO dateNov 27, 2015
Founded at2007
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
359.00
+0.84%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Director
Independent Director
--
--
Ms. Kim Golodetz
Ms. Kim Golodetz
IR Contact Officer
IR Contact Officer
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Director
Director
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
359.00
+0.84%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Director
Independent Director
--
--
Ms. Kim Golodetz
Ms. Kim Golodetz
IR Contact Officer
IR Contact Officer
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Geode Capital Management, L.L.C.
0.74%
Sabby Management, LLC
0.30%
Frelick (Jeffrey)
0.07%
Walsh (Deina H)
0.06%
Tower Research Capital LLC
0.06%
Other
98.78%
Shareholders
Shareholders
Proportion
Geode Capital Management, L.L.C.
0.74%
Sabby Management, LLC
0.30%
Frelick (Jeffrey)
0.07%
Walsh (Deina H)
0.06%
Tower Research Capital LLC
0.06%
Other
98.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
1.04%
Individual Investor
0.12%
Hedge Fund
0.06%
Other
98.78%
Institutional Shareholding
Updated: Mon, Mar 3
Updated: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
27
74.14K
2.27%
-185.13K
2024Q4
36
139.64K
4.27%
-177.16K
2024Q3
35
174.78K
6.98%
-106.17K
2024Q2
34
138.99K
16.02%
-43.94K
2024Q1
34
123.42K
15.56%
-19.42K
2023Q4
32
43.06K
6.51%
-99.40K
2023Q3
31
101.95K
29.59%
-11.73K
2023Q2
29
107.23K
61.29%
+36.20K
2023Q1
27
41.68K
59.89%
-1.33K
2022Q4
21
42.77K
70.99%
+9.36K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Geode Capital Management, L.L.C.
15.36K
0.47%
--
--
Dec 31, 2024
Sabby Management, LLC
9.88K
0.3%
+9.88K
--
Dec 31, 2023
Frelick (Jeffrey)
2.14K
0.07%
-13.00
-0.60%
Feb 19, 2025
Walsh (Deina H)
1.88K
0.06%
--
--
Feb 19, 2025
Tower Research Capital LLC
3.39K
0.1%
+1.60K
+89.64%
Dec 31, 2024
BofA Global Research (US)
20.00
0%
+6.00
+42.86%
Dec 31, 2024
Meikle (Phillip Terry II)
10.00
0%
+10.00
--
Feb 19, 2025
UBS Financial Services, Inc.
21.87K
0.67%
-10.98K
-33.44%
Dec 31, 2024
Carson Wealth Management Group
--
0%
-444.00
-100.00%
Dec 31, 2024
Citi Investment Research (US)
4.95K
0.15%
+4.95K
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 18, 2023
Merger
8<1
Dec 18, 2023
Merger
8<1
Dec 18, 2023
Merger
8<1
Dec 18, 2023
Merger
8<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Date
Type
Ratio
Dec 18, 2023
Merger
8<1
Dec 18, 2023
Merger
8<1
Dec 18, 2023
Merger
8<1
Dec 18, 2023
Merger
8<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
KeyAI